Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx Industry Will Win Fight Over Cost-Effectiveness, Pfizer Predicts

This article was originally published in The Pink Sheet Daily

You may also be interested in...



Pfizer Optimistic On Florida Medicaid Program As State Moves To Let Contract Expire

Legislation signed by Gov. Jeb Bush would end the Pfizer "Healthy State" program when the contract expires in September 2005. A state report suggests savings from the program have barely exceeded costs. Pfizer expects a report due in August to prove the value of its disease management initiative.

Pfizer Optimistic On Florida Medicaid Program As State Moves To Let Contract Expire

Legislation signed by Gov. Jeb Bush would end the Pfizer "Healthy State" program when the contract expires in September 2005. A state report suggests savings from the program have barely exceeded costs. Pfizer expects a report due in August to prove the value of its disease management initiative.

"Pfizer Pfriends" Discount Program Offers Medicare Card Model To Uninsured

The company will provide discounts through a two-tiered structure to people who lack drug coverage, regardless of age or income level. The discounts range from 15% to 37% off of retail prices for Pfizer products. Pfizer will publicize the discounted prices via a website and call center that will launch in August.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060077

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel